Aquestive Therapeutics, Inc. (AQST) is an international leading company providing therapeutics to patients with unmet medical needs. The company manufactures orally-administered therapeutics for the delivery of complex molecules. The product line of the company includes Sympazan for treating seizures related to Lennox-Gastaut syndrome. Also, it is focusing on developing pipeline products linked with CNS diseases and anaphylaxis.
The price of AQST stock in the regular trading on March 8, 2022, with a drop of 4.08% was $2.82. Its price further dived by 6.03% at the last check of the aftermarket session.
AQST: Key Financial
On March 8, 2022, AQST reported its unaudited and consolidated financial statement for the fourth fiscal quarter of 2021 concluded December 31, 2021. Some highlights are cited here.
Revenue
Net revenues of the company in the fourth fiscal quarter of 2021 were $11.1 million against $7.1 million for the same quarter of the prior year. The company observed an increase of 55% in its net revenue YoY.
EPS
Net loss basic and diluted during Q4 2021 was $28.9 million or $0.72 per share in comparison to $20.4 million or $0.60 per share during the same period of 2020. The company noted a substantial drop in its earnings YoY.
AQST: Events and Happenings
On March 03, 2022, AQST reported its entry into a deal with Haisco Pharmaceutical Group Co., Ltd. for the licensing, development, and commercialization of EXSERVAN exclusively for treating amyotrophic lateral sclerosis.
On February 28, 2022, AQST updated on its poster presentation announcing optimistic topline results from AQST-109 Phase 1 trials at the annual meeting of the American Academy of Allergy, Asthma, and Immunology held on February 25-28. On January 07, 2022, AQST informed about its top management’s participation at the Virtual H.C. Wainwright BioConnect Conference held on January 10-13, 2022.
Conclusion
AQST stock is down by 33% YTD. Its aftermarket stats showed a declining trend as the company announced its fourth fiscal quarter financials. The company’s EPS declined over the year but its revenue gained a hefty 55% over the year. For the first fiscal quarter of 2022, the revenue guidance of the company is $9.36 million versus -$0.46 EPS.
